WO2001075178A3 - Methods for identifying peptide aptamers capable of altering a cell phenotype - Google Patents

Methods for identifying peptide aptamers capable of altering a cell phenotype Download PDF

Info

Publication number
WO2001075178A3
WO2001075178A3 PCT/US2001/010953 US0110953W WO0175178A3 WO 2001075178 A3 WO2001075178 A3 WO 2001075178A3 US 0110953 W US0110953 W US 0110953W WO 0175178 A3 WO0175178 A3 WO 0175178A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell phenotype
altering
methods
peptide aptamers
identifying peptide
Prior art date
Application number
PCT/US2001/010953
Other languages
French (fr)
Other versions
WO2001075178A2 (en
Inventor
John D Benson
Sylvie Magali Vincent
Bradley Bryan Brasher
Original Assignee
Enanta Pharm Inc
John D Benson
Sylvie Magali Vincent
Bradley Bryan Brasher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc, John D Benson, Sylvie Magali Vincent, Bradley Bryan Brasher filed Critical Enanta Pharm Inc
Priority to AU2001289284A priority Critical patent/AU2001289284A1/en
Publication of WO2001075178A2 publication Critical patent/WO2001075178A2/en
Publication of WO2001075178A3 publication Critical patent/WO2001075178A3/en
Priority to US10/263,577 priority patent/US20030108532A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries

Abstract

The invention provides methods and compositions for screening and identifying peptide aptamers that can modulate a cell phenotype and further, can be used for the treatment of a disease involving a misregulated cell phenotype, such as, for example, a cancer.
PCT/US2001/010953 2000-04-04 2001-04-04 Methods for identifying peptide aptamers capable of altering a cell phenotype WO2001075178A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001289284A AU2001289284A1 (en) 2000-04-04 2001-04-04 Methods for identifying peptide aptamers capable of altering a cell phenotype
US10/263,577 US20030108532A1 (en) 2000-04-04 2002-10-03 Methods for identifying peptide aptamers capable of altering a cell phenotype

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19472200P 2000-04-04 2000-04-04
US60/194,722 2000-04-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/263,577 Continuation US20030108532A1 (en) 2000-04-04 2002-10-03 Methods for identifying peptide aptamers capable of altering a cell phenotype

Publications (2)

Publication Number Publication Date
WO2001075178A2 WO2001075178A2 (en) 2001-10-11
WO2001075178A3 true WO2001075178A3 (en) 2002-06-06

Family

ID=22718675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010953 WO2001075178A2 (en) 2000-04-04 2001-04-04 Methods for identifying peptide aptamers capable of altering a cell phenotype

Country Status (3)

Country Link
US (1) US20030108532A1 (en)
AU (1) AU2001289284A1 (en)
WO (1) WO2001075178A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US20030134329A1 (en) * 2001-10-09 2003-07-17 Thea Norman Cross-species bioactive peptides
AU2002361589A1 (en) * 2001-11-06 2003-05-19 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
WO2004001044A1 (en) * 2002-06-21 2003-12-31 Sinogenomax Company Ltd. Randomised dna libraries and double-stranded rna libraries, use and method of production thereof
US20050052687A1 (en) * 2003-08-12 2005-03-10 Murata Kikai Kabushiki Kaisha Image processing device and communication terminal device
US20110218118A1 (en) * 2004-06-03 2011-09-08 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
EP2563380B1 (en) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
EP2566515B1 (en) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
JP6008840B2 (en) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl αtRNA synthetase
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
JP6116479B2 (en) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase
EP3311847A1 (en) 2012-02-16 2018-04-25 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
ES2774549T3 (en) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragments of P97 and uses thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038553A1 (en) * 1995-06-02 1996-12-05 M&E Biotech A/S A method for identification of biologically active peptides and nucleic acids
WO1999024617A1 (en) * 1997-11-06 1999-05-20 Ventana Genetics, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
WO2000020574A2 (en) * 1998-10-08 2000-04-13 Rigel Pharmaceuticals, Inc. Fusions of scaffold proteins with random peptide libraries

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528266A (en) * 1979-10-01 1985-07-09 George Pieczenik Method of inserting unique DNA sequences into DNA vectors
DE3588239T3 (en) * 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe A method for obtaining DNA, RNA, peptides, polypeptides or proteins by DMS recombinant methods
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5136779A (en) * 1989-09-27 1992-08-11 Die Tech, Inc. Method of mounting lead frame on substrate
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5753432A (en) * 1990-10-19 1998-05-19 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with control of neoplastic transformation in mammalian cells
US5830725A (en) * 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US6455247B1 (en) * 1996-01-23 2002-09-24 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US5998136A (en) * 1996-08-19 1999-12-07 Arcaris, Inc. Selection systems and methods for identifying genes and gene products involved in cell proliferation
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038553A1 (en) * 1995-06-02 1996-12-05 M&E Biotech A/S A method for identification of biologically active peptides and nucleic acids
WO1999024617A1 (en) * 1997-11-06 1999-05-20 Ventana Genetics, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
WO2000020574A2 (en) * 1998-10-08 2000-04-13 Rigel Pharmaceuticals, Inc. Fusions of scaffold proteins with random peptide libraries

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLUM JONATHAN H ET AL: "Isolation of peptide aptamers that inhibit intracellular processes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 5, 29 February 2000 (2000-02-29), Feb. 29, 2000, pages 2241 - 2246, XP002193741, ISSN: 0027-8424 *
CAPONIGRO GIORDANO ET AL: "Transdominant genetic analysis of a growth control pathway.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 13, 23 June 1998 (1998-06-23), June 23, 1998, pages 7508 - 7513, XP002193743, ISSN: 0027-8424 *
GEYER C RONALD ET AL: ""Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 15, 20 July 1999 (1999-07-20), July 20, 1999, pages 8567 - 8572, XP002193742, ISSN: 0027-8424 *
LADNER R C: "Constrained peptides as binding entities", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 13, no. 10, October 1995 (1995-10-01), pages 426 - 430, XP002135011, ISSN: 0167-7799 *

Also Published As

Publication number Publication date
WO2001075178A2 (en) 2001-10-11
AU2001289284A1 (en) 2001-10-15
US20030108532A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
AU2002344842A1 (en) Highly impact-resistant granules
WO2005051178A3 (en) Marker for neuromyelitis optica
MXPA03007983A (en) Process for the preparation of middle distillates.
WO2003066802A3 (en) Gene expression analysis using nicking agents
WO2001083547A3 (en) Anti-inflammatory compounds and uses thereof
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
WO2002030353A3 (en) NF-λB INHIBITORS
YU2903A (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same
WO2004058153A9 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO1999025843A3 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
AU2002231295A1 (en) Developed seed and methods for making the same
WO2006015191A3 (en) Multicyclic lonidamine analogs
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
WO2004062571A3 (en) Substantially pure cilostazol and processes for making same
WO2003020213A3 (en) Methods and compositions for treating inflammatory disorders
WO2003087051A3 (en) Methods for identifying allosteric sites
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2003026632A3 (en) Substituted phenol compounds useful for anesthesia and sedation
WO2003030719A3 (en) Methods and kits for use in selecting approaches to treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10263577

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP